Form 4: Day One Biopharmaceuticals Executive Samuel Blackman Sells 30,000 Shares

Samuel Blackman, Head of R&D at Day One Biopharmaceuticals, sold 30,000 shares of common stock on March 11, 2024, at a weighted average price of $15.2438 per share.

Summary

• On March 11, 2024, Samuel C. Blackman, Head of R&D at Day One Biopharmaceuticals, sold 30,000 shares of the company's common stock.
• The shares were sold at a weighted average price of $15.2438.
• The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on October 10, 2023.
• Following the transaction, Blackman directly owns 1,194,662 shares of Day One Biopharmaceuticals.
• Blackman also indirectly owns 1,000,000 shares through the 2021 Blackman Family LLC, where he is the sole manager and shares voting and dispositive power with his wife.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, reporting an insider stock sale. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about the transaction.

Industry Context

Insider sales are a common occurrence in publicly traded companies. They can be driven by a variety of factors, including personal financial planning and diversification. It's important to consider the context of the sale, such as the executive's overall holdings and whether the sale was pre-planned under a 10b5-1 trading plan.

Stakeholder Impact

• The stock sale could have a minor negative impact on shareholder sentiment, although the existence of a pre-arranged trading plan mitigates this concern.

Key Dates